• 1
    Sharman WM, Allen CM, Van Lier JE. Photodynamic therapeutics: basic principles and clinical applications. Drug Discov Today 1999; 4:50717.
  • 2
    Boyle RW, Dolphin D. Structure and biodistribution relationships of photodynamic sensitizers. Photochem Photobiol 1996; 64:46985.
  • 3
    Brown SB, Brown EA, Walker I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol 2004; 5:497508.
  • 4
    Konan YN, Gurny R, Allemann E. State of the art in the delivery of photosensitizers for photodynamic therapy. J Photochem Photobiol B-Biol 2002; 66:89106.
  • 5
    Van Dongen GAMS. Photosensitiser-antibody conjugates for detection and therapy of cancer. Adv Drug Deliv Rev 2004; 56:3152.
  • 6
    Mew D, Wat CK, Towers GHN, Levy JG. Photoimmunotherapy: treatment of animal tumours with tumour-specific monoclonal antibody–hematoporhyrin conjugates. J Immunol 1983; 130:14737.
  • 7
    Oseroff AR, Ara G, Ohuoha D, Aprille J, Bommer JC, Yarmush ML, Foley J, Cincotta L. Strategies for selective cancer photochemotherapy: antibody targeted and selective carcinoma cell photolysis. Photochem Photobiol 1987; 46:8396.
  • 8
    Vrouenraets MB, Visser GWM, Steward FA, Stigter M, Oppelaar H, Postmus PE, Snow GB, Van Dongen GAMS. Development of meta-tetraxydroxyphenylchlorin–monoclonal antibody conjugates for photoimmunotherapy. Cancer Res 1999; 59:150513.
  • 9
    Carcenac M, Larroque C, Langlois R, Van Lier JE, Artus JC, Pelegrin A. Preparation, phototoxicity and biodistribution studies of anti-carcinoembryonic antigen monoclonal antibody-phthalocyanine. Photochem Photobiol 1999; 70:9306.
  • 10
    Hudson R, Carcenac M, Smith KA, Madden L, Clarke OJ, Pelegrin A, Greenman J, Boyle RW. The development and characterisation of porphyrin isothiocyanate-monoclonal antibody conjugates for photoimmunotherapy. Br J Cancer 2005; 92:14429.
  • 11
    Trail PA, King HD, Dubowchik GM. Monoclonal antibody drug immunoconjugates for targeted treatment of cancer. Cancer Immunol Immunother 2003; 52:32837.
  • 12
    Smith KA, Nelson PN, Warren P, Astley SJ, Murray PG, Greenman J. Demystified. recombinant antibodies. J Clin Pathol 2004; 57:9127.
  • 13
    Russeva MG, Adams GP. Radioimmunotherapy with engineered antibodies. Expert Opin Biol Ther 2004; 4:21731,.
  • 14
    Bradbury ARM, Marks JD. Antibodies from phage antibody libraries. J Immunol Meth 2004; 290:2949.
  • 15
    Chester K, Pedley B, Tolner B et al. Engineering antibodies for clinical applications in cancer. Tumour Biol 2004; 25:918.
  • 16
    Goff BA, Bamberg M, Hasan T. Photoimmunotherapy of human ovarian carcinoma cells ex vivo. Cancer Res 1991; 51:47627.
  • 17
    Hamblin MR, Miller JL, Hasan T. Effect of charge on the interaction of site-specific photoimmunoconjugates with human ovarian cancer cells. Cancer Res 1996; 56:520510.
  • 18
    Clarke OJ, Boyle RW. Isothiocyanatoporphyrins, useful intermediates for the conjugation of porphyrins with biomolecules and solid supports. Chem Commun 1999; 21:2231.
  • 19
    Sutton JM, Clarke OJ, Fernandez N, Boyle RW. Porphyrin, chlorin, and bacteriochlorin isothiocyanates. useful reagents for the synthesis of photoactive bioconjugates. Bioconjugate Chem 2002; 13:24963.
  • 20
    Topping K, Hough VC, Monson JRT, Greenman J. Isolation of human colorectal tumour reactive antibodies using phage display technology. Int J Oncol 2000; 16:18795.
  • 21
    Nissim A, Hoogenboom HR, Tomlison IM, Flynn G, Midgley C, Lane D, Winter G. Antibody fragments from a single pot phage display library as immunochemical reagents. EMBO J 1994; 13:6928,.
  • 22
    Birchler M, Viti F, Zardi L, Spiess B, Neri D. Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment. Nat Biotechnol 1999; 17:9848.
  • 23
    Oleinick NL, Morris RL, Belichenko T. The role of apoptosis in response to photodynamic therapy. What, where, why, and how. Photochem Photobiol Sci 2002; 1:121.
  • 24
    Biel MA. Photodynamic therapy in head and neck cancer. Curr Oncol Rep 2002; 4:8796.